Log In
Print
BCIQ
Print
Print this Print this
 

HerpV (formerly AG-707 plus QS-21)

  Manage Alerts
Collapse Summary General Information
Company Agenus Inc.
DescriptionVaccine consisting of recombinant heat shock protein 70 (Hsp70) complexed with 32 distinct 35-mer synthetic peptides from the human herpes simplex type 2 (HSV-2) proteome with Agenus' QS-21 Stimulon adjuvant
Molecular Target
Mechanism of ActionVaccine
Therapeutic ModalityActive immunotherapy
Latest Stage of DevelopmentPhase II
Standard IndicationHerpes simplex virus (HSV)
Indication DetailsTreat genital herpes caused by herpes simplex virus type 2 (HSV-2) infection
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today